{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:58Z","timestamp":1791911818157,"version":"4.3.4"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100019016","name":"Assessment of Spondyloarthritis international Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To summarize evidence on the relationship between early treatment (definition based on symptom\/disease duration or radiographic damage) and treatment clinical response in patients with SpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review was conducted in studies on SpA patients treated with NSAIDs or biological\/targeted synthetic DMARDs addressing the impact of symptom\/disease duration or presence of radiographic damage on treatment response assessed by any disease activity outcome. For categorical outcomes, relative risk, relative risk ratio and number needed to treat were calculated, and for continuous outcomes, differences in differences, to compare groups stratified based on symptom\/disease duration or the presence of radiographic damage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From the 8769 articles retrieved, 25 were included and 2 added by hand-search, all in axial SpA (axSpA), most of them with low risk of bias. Twenty-one studies compared groups based on symptom duration (n\u2009=\u20096) or disease duration (n\u2009=\u200915) and seven studies based on absence\/presence of radiographic damage (two studies used two comparisons). When early axSpA was defined by symptom duration (&amp;lt;5\u2009years) in randomized controlled trials, early treatment was associated with better outcomes in patients with non-radiographic axSpA [n\u2009=\u20092, ASAS40 relative risk ratio 5.24 (95% CI 1.12, 24.41) and 1.52 (0.60, 3.87)] but not in radiographic axSpA (n\u2009=\u20091) [ASAS20 0.96 (0.53\u20131.73)]. When early axSpA was defined based on disease duration or radiographic damage, no differences were found between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Evidence towards better outcomes in early axSpA is very limited and restricted to non-radiographic axSpA and &amp;lt;5\u2009years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac532","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T15:59:43Z","timestamp":1663084783000},"page":"1398-1409","source":"Crossref","is-referenced-by-count":30,"title":["Treating spondyloarthritis early: does it matter? Results from a systematic literature review"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-0416","authenticated-orcid":false,"given":"Dafne","family":"Capelusnik","sequence":"first","affiliation":[{"name":"Department of Medicine, Care and Public Health Research Institute CAPHRI, Faculty of Health, Medicine and Life Sciences , Maastricht University, Maastricht, The Netherlands"},{"name":"Department of Rheumatology, Instituto de Rehabilitaci\u00f3n Psicof\u00edsica (IREP) , Ciudad de Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-5330","authenticated-orcid":false,"given":"Diego","family":"Benavent","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario La Paz, IdiPaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Amsterdam University Medical Center , Amsterdam, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectiology and Rheumatology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-0683","authenticated-orcid":false,"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, and School for Public Health and Primary Care (CAPHRI), Maastricht University , Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-6056","authenticated-orcid":false,"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[{"name":"University of Sheffield, Sheffield , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario La Paz, IdiPaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","article-title":"Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts","volume":"74","author":"van Nies","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","article-title":"Understanding the window of opportunity concept in early rheumatoid arthritis","volume":"48","author":"Boers","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","article-title":"Treatment strategies in axial spondyloarthritis: what, when and how?","volume":"59","author":"Fragoulis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar4561","article-title":"The window of opportunity: a relevant concept for axial spondyloarthritis","volume":"16","author":"Robinson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials","volume":"42","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"152032","DOI":"10.1016\/j.semarthrit.2022.152032","article-title":"How is early spondyloarthritis defined in the literature? Results from a systematic review","volume":"55","author":"Benavent","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/088506660101600307","article-title":"Evidence-based medicine: how to practice and teach EBM, 2nd Edition: by David L. Sackett, Sharon E. Straus, W. Scott Richardson, William Rosenberg, and R. Brian Haynes, Churchill Livingstone, 2000","volume":"16","author":"Luckmann","year":"2001","journal-title":"J Intens Care Med"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am J Manag Care"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/rheumatology\/keaa807","article-title":"Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/appi.ps.54.2.145","article-title":"Psychopharmacology: number needed to treat: an underused measure of treatment effect","volume":"54","author":"Pinson","year":"2003","journal-title":"Psychiatr Serv"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/302778","article-title":"The relationship between the sibling recurrence-risk ratio and genotype relative risk","volume":"66","author":"Rybicki","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/restud\/rdx049","article-title":"Fuzzy differences-in-differences","volume":"85","author":"de Chaisemartin","year":"2018","journal-title":"Rev Econ Stud"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"e000917","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-017-3965-2","article-title":"Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42358-018-0040-x","article-title":"Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors","volume":"58","author":"Shimabuco","year":"2018","journal-title":"Adv Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40744-020-00197-5","article-title":"Improvement of function and its determinants in a group of axial spondyloarthritis patients treated with TNF inhibitors: a real-life study","volume":"7","author":"Lubrano","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","article-title":"Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/rheumatology\/kew230","article-title":"Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/art.38613","article-title":"Effectiveness of tumor necrosis factor \u03b1 blockers in early axial spondyloarthritis: data from the DESIR cohort","volume":"66","author":"Molt\u00f3","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3899\/jrheum.150372","article-title":"Tumor necrosis factor-\u03b1 inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug survival, and patient outcome","volume":"42","author":"Corli","year":"2015","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","article-title":"Earlier treatment of non-radiographic axial spondyloarthritis with certolizumab pegol results in improved clinical and patient-reported outcomes [abstract]","volume":"71","author":"Kay","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"2023040420430243700_","first-page":"878","article-title":"FRI0388 Secukinumab improves health-related quality of life in patients with ankylosing spondylitis, irrespective of time since first diagnosis: pooled results from the secukinumab phase 3 trial program","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","article-title":"Impact of age and disease duration on the response to IL-17A inhibitor (secukinumab) treatment in ankylosing spondylitis: pooled results from the phase 3 MEASURE studies [abstract]","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023040420430243700_","article-title":"Response to treatment with ixekizumab in patients with active non-radiographic axial spondyloarthritis based on HLA-B27 status and disease duration [abstract]","volume":"72","author":"Navarro-Comp\u00e1n","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023040420430243700_","article-title":"Predicting ASDAS inactive disease after 6 months of TNFi treatment in bio-naive axial spondyloarthritis patients treated in clinical practice \u2013 results from the EuroSpA collaboration [abstract]","volume":"71","author":"\u00d8rnbjerg","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023040420430243700_"},{"key":"2023040420430243700_","year":"2009"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann Intern Med"},{"key":"2023040420430243700_","first-page":"1747","article-title":"Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study","volume":"15","author":"Borg","year":"1988","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","first-page":"2208","article-title":"Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study","volume":"22","author":"Egsmose","year":"1995","journal-title":"J Rheumatol"},{"key":"2023040420430243700_","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"van Nies","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac532\/46205476\/keac532.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1398\/49750545\/keac532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1398\/49750545\/keac532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T21:31:39Z","timestamp":1701034299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/4\/1398\/6696709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac532","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,9,13]]}}}